Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.
Author(s): Houston JP, Fijal B, Heinloth AN, Adams DH
Affiliation(s): Lilly USA, LLC, Indianapolis, IN 46285, USA. houston_john_p@lilly.com
Publication date & source: 2010-01-30, Psychiatry Res., 175(1-2):171-2. Epub 2009 Nov 5.
Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial
In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment.
|